💼 My Portfolio 👁 Watchlist 🧠 AI Stock Analysis 🤖 AI Portfolio Analysis 📊 Fear & Greed 💬 Community 🔴 Live 📰 Archives 🛒 Shop

← Back to Screener

C4 Therapeutics

CCCC Small Cap

Healthcare · Biotechnology

Updated: May 22, 2026, 22:06 UTC

$3.56
+1.14% today
52W: $1.21 – $3.95
52W Low: $1.21 Position: 85.8% 52W High: $3.95

Key Metrics

P/E Ratio
—
Price-to-Earnings
Forward P/E
—
Forward Price/Earnings
P/S Ratio
11.29x
Price-to-Sales
EV/EBITDA
—
Enterprise Value/EBITDA
Div. Yield
—
Annual dividend yield
Market Cap
$393.6M
Market Capitalization
Revenue Growth
-15%
YoY Revenue Growth
Profit Margin
-297.76%
Net profit margin
ROE
-48.35%
Return on Equity
Beta
—
Market sensitivity
Short Interest
19.24%
% of float sold short
Avg. Volume
3,099,993
Average daily volume

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Strong Buy
7 analysts
Avg. Price Target
$11.57
+225.04% upside
Target Range
$6.00 – $30.00

About the Company

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGA

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 104 Exchange: NMS

C4 Therapeutics Stock at a Glance

C4 Therapeutics (CCCC) is currently trading at $3.56 with a market capitalization of $393.6M. The 52-week range spans from $1.21 to $3.95; the current price is 9.9% below the yearly high. Year-over-year revenue growth stands at -15.0%.

💰 Dividend

C4 Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

7 analysts rate C4 Therapeutics (CCCC) on consensus: Strong Buy. The average price target is $11.57, implying +225.04% from the current price. Analyst price targets range from $6.00 to $30.00.

Investment Thesis: Strengths & Weaknesses

Strengths
  • High gross margin of 74.25% — indicates pricing power
  • Analyst consensus: Strong Buy
  • Solid balance sheet with low debt (D/E 24.95)
Weaknesses
  • –Revenue shrinking (-15% YoY)
  • –Currently unprofitable
  • –High short interest (19.24%)
  • –Negative free cash flow

Technical Snapshot

50-Day MA
$2.89
+23.18% vs. price
200-Day MA
$2.53
+40.71% vs. price
Below 52W High
−9.9%
$3.95
Above 52W Low
+194.2%
$1.21

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

Short Interest
19.24% · High
% of float sold short
Debt-to-Equity
24.95 · Low
Total debt / equity

The data points to elevated short interest (19.24%).

Trading Data

50-Day MA: $2.89
200-Day MA: $2.53
Volume: 1,706,176
Avg. Volume: 3,099,993
Short Ratio: 7.14
P/B Ratio: 1.58x
Debt/Equity: 24.95x
Free Cash Flow: $-50,534,752

C4 Therapeutics (CCCC) 2026: 3,56 USD US Targeted-Protein-Degradation Biotech with Cemsidomide Lead Asset and Roche-Biogen Strategic Collaborations

The Real Story

C4 Therapeutics Inc. (NASDAQ: CCCC) is a Watertown, Massachusetts-headquartered clinical-stage biopharmaceutical company developing targeted-protein-degradation therapies (TPD). Lead asset: Cemsidomide (orally bioavailable MonoDAC degrader, Phase 1/2 for multiple-myeloma-and-non-Hodgkin-lymphoma). Strategic-collaborations: Roche (oncology TPD), Biogen (CNS TPD). Platform technologies: BiDAC (bifunctional) and MonoDAC.

What Smart Money Thinks

C4 Therapeutics has biotech-pipeline-investor base. Roche via strategic-collaboration plus equity-stake. BlackRock at approximately 6,8 percent, RA Capital at approximately 5,4 percent. Short-interest sits at approximately 12 percent of float as of May 2026.

Explore the BMI Smart-Money Tracker →

📈 The 3 Real Bull Points

#1 Cemsidomide Phase 1/2 readout potential 2026-2027 — peak-revenue 600-900 million USD if approved

Cemsidomide Phase 1/2 readout 2026-2027 for multiple-myeloma-and-NHL plus oncology indications. Approval probability 35-55 percent supports 600-900 million USD peak-revenue opportunity.

#2 Roche and Biogen strategic collaborations validate TPD platform

Roche-and-Biogen collaborations provide platform-validation plus milestone-payment revenue.

#3 TPD industry platform-economics support multiple programs and acquisition optionality

Targeted-protein-degradation industry-economics support multi-program-pipeline and eventual-acquisition optionality.

📉 The 3 Real Bear Points

#1 Phase 1/2 binary risk — negative readout would compress fair-value 50-70 percent

Cemsidomide Phase 1/2 readout binary clinical-trial event.

#2 Pre-profit operating burn requires continued capital-raise

Continued capital-raise creates dilution.

#3 TPD competitive intensity from Kymera, Arvinas, Foghorn, BMS Celgene CELMoD

Crowded TPD-field compresses C4 differentiation.

Valuation in Context

C4 Therapeutics at 3,56 USD per share with approximately 110,6 million shares outstanding has a market capitalization of approximately 394 million USD. Pre-profit operating profile.

Risk-adjusted DCF on Cemsidomide success supports 7-11 USD price range. Bear-case 1,50-2,00 USD. Bull-case 14-18 USD.

🗓️ Next 3 Catalyst Dates

  1. 2026 Q4:

    Cemsidomide Phase 1/2 expanded readout.

  2. 2027 Q2:

    Q1 2027 earnings plus pipeline update.

  3. 2027 H2:

    Pivotal-trial-initiation potential.

💬 Daniel's Take

C4 Therapeutics is a targeted-protein-degradation biotech with Cemsidomide Phase 1/2 readout binary, Roche-Biogen collaborations and TPD platform optionality. Position-sizing: 0,2–0,5 percent.

Sources (3)

Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.

Where can I buy C4 Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top
WordPress Cookie Notice by Real Cookie Banner